BR112022017089A2 - Derivados de piridazina para modular o splicing de ácido nucleico - Google Patents
Derivados de piridazina para modular o splicing de ácido nucleicoInfo
- Publication number
- BR112022017089A2 BR112022017089A2 BR112022017089A BR112022017089A BR112022017089A2 BR 112022017089 A2 BR112022017089 A2 BR 112022017089A2 BR 112022017089 A BR112022017089 A BR 112022017089A BR 112022017089 A BR112022017089 A BR 112022017089A BR 112022017089 A2 BR112022017089 A2 BR 112022017089A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- pyridazine derivatives
- splicing
- acid splicing
- modulate nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Replacement Of Web Rolls (AREA)
Abstract
DERIVADOS DE PIRIDAZINA PARA MODULAR SPLICING DE ÁCIDO NUCLEICO. A presente invenção refere-se a compostos e composições relacionados que, entre outros, modulam splicing de ácido nucleico, por exemplo, splicing de um pré-mRNA, assim como métodos de uso dos mesmos.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983537P | 2020-02-28 | 2020-02-28 | |
US202063007134P | 2020-04-08 | 2020-04-08 | |
US202063040474P | 2020-06-17 | 2020-06-17 | |
US202063072781P | 2020-08-31 | 2020-08-31 | |
US202063126491P | 2020-12-16 | 2020-12-16 | |
PCT/US2021/020160 WO2021174170A1 (en) | 2020-02-28 | 2021-02-28 | Pyridazine dervatives for modulating nucleic acid splicing |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017089A2 true BR112022017089A2 (pt) | 2022-11-16 |
Family
ID=75278334
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017107A BR112022017107A2 (pt) | 2020-02-28 | 2021-02-28 | Derivados de piridazina para modulação de splicing de ácido nucleico |
BR112022017089A BR112022017089A2 (pt) | 2020-02-28 | 2021-02-28 | Derivados de piridazina para modular o splicing de ácido nucleico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017107A BR112022017107A2 (pt) | 2020-02-28 | 2021-02-28 | Derivados de piridazina para modulação de splicing de ácido nucleico |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230365526A1 (pt) |
EP (2) | EP4110774A1 (pt) |
JP (2) | JP2023515617A (pt) |
KR (2) | KR20220157407A (pt) |
CN (2) | CN115551847A (pt) |
AU (3) | AU2021228286A1 (pt) |
BR (2) | BR112022017107A2 (pt) |
CA (2) | CA3169643A1 (pt) |
IL (2) | IL295954A (pt) |
MX (2) | MX2022010634A (pt) |
WO (2) | WO2021174170A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122020005073A2 (pt) | 2017-08-04 | 2020-10-13 | Skyhawk Therapeutics, Inc. | Composto, composição farmacêutica e uso do composto |
EP3920915A4 (en) * | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
CN113677344A (zh) | 2019-02-06 | 2021-11-19 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
CN116997548A (zh) | 2020-05-13 | 2023-11-03 | Chdi基金会股份有限公司 | 用于治疗亨廷顿病的htt调节剂 |
WO2023034836A1 (en) * | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
WO2023034827A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
WO2023081858A1 (en) * | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed-pyrazine amine derivatives for treating sca3 |
WO2023143605A1 (en) * | 2022-01-31 | 2023-08-03 | Novartis Ag | Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents |
WO2024042316A1 (en) * | 2022-08-22 | 2024-02-29 | Redx Pharma Plc. | Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201609188WA (en) | 2012-02-10 | 2016-12-29 | Ptc Therapeutics Inc | Compounds for treating spinal muscular atrophy |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
BR112016002083B1 (pt) * | 2013-07-31 | 2020-04-07 | Sumitomo Chemical Co | composto tetrazolinona, seu uso, agente e método de controle de peste |
MX2017005715A (es) * | 2014-10-31 | 2018-02-23 | Massachusetts Gen Hospital | Potentes moduladores de gamma-secretasa. |
WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
PL3386511T3 (pl) * | 2015-12-10 | 2021-11-08 | Ptc Therapeutics, Inc. | Sposoby leczenia choroby huntingtona |
WO2018098446A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Methods for modulating rna splicing |
CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
BR122020005073A2 (pt) * | 2017-08-04 | 2020-10-13 | Skyhawk Therapeutics, Inc. | Composto, composição farmacêutica e uso do composto |
KR20200057071A (ko) | 2017-09-25 | 2020-05-25 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물 |
KR20200074164A (ko) * | 2017-10-20 | 2020-06-24 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 길항제 |
CN111788182B (zh) * | 2018-02-02 | 2023-09-26 | 范德堡大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
US11530207B2 (en) | 2018-04-10 | 2022-12-20 | Skyhawk Therapeutics, Inc. | Compounds for the treatment of cancer |
TWI823932B (zh) * | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲(江蘇)醫藥有限公司 | 三唑并嘧啶化合物及其在治療癌症中之用途 |
-
2021
- 2021-02-28 CN CN202180030690.3A patent/CN115551847A/zh active Pending
- 2021-02-28 IL IL295954A patent/IL295954A/en unknown
- 2021-02-28 EP EP21715355.0A patent/EP4110774A1/en active Pending
- 2021-02-28 JP JP2022552203A patent/JP2023515617A/ja active Pending
- 2021-02-28 US US17/802,747 patent/US20230365526A1/en active Pending
- 2021-02-28 WO PCT/US2021/020160 patent/WO2021174170A1/en unknown
- 2021-02-28 BR BR112022017107A patent/BR112022017107A2/pt unknown
- 2021-02-28 WO PCT/US2021/020173 patent/WO2021174176A1/en unknown
- 2021-02-28 KR KR1020227033652A patent/KR20220157407A/ko unknown
- 2021-02-28 CA CA3169643A patent/CA3169643A1/en active Pending
- 2021-02-28 US US17/802,702 patent/US20230140983A1/en active Pending
- 2021-02-28 BR BR112022017089A patent/BR112022017089A2/pt unknown
- 2021-02-28 MX MX2022010634A patent/MX2022010634A/es unknown
- 2021-02-28 IL IL295953A patent/IL295953A/en unknown
- 2021-02-28 MX MX2022010637A patent/MX2022010637A/es unknown
- 2021-02-28 KR KR1020227033654A patent/KR20220158236A/ko unknown
- 2021-02-28 CA CA3169667A patent/CA3169667A1/en active Pending
- 2021-02-28 EP EP21713826.2A patent/EP4110771A1/en active Pending
- 2021-02-28 JP JP2022552206A patent/JP2023515618A/ja active Pending
- 2021-02-28 AU AU2021228286A patent/AU2021228286A1/en not_active Abandoned
- 2021-02-28 AU AU2021228288A patent/AU2021228288A1/en active Pending
- 2021-02-28 CN CN202180031321.6A patent/CN115551843A/zh active Pending
-
2024
- 2024-03-08 AU AU2024201568A patent/AU2024201568A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021174176A1 (en) | 2021-09-02 |
JP2023515617A (ja) | 2023-04-13 |
CN115551843A (zh) | 2022-12-30 |
AU2021228288A1 (en) | 2022-09-22 |
IL295953A (en) | 2022-10-01 |
US20230365526A1 (en) | 2023-11-16 |
WO2021174176A9 (en) | 2022-09-15 |
WO2021174170A1 (en) | 2021-09-02 |
IL295954A (en) | 2022-10-01 |
US20230140983A1 (en) | 2023-05-11 |
JP2023515618A (ja) | 2023-04-13 |
BR112022017107A2 (pt) | 2022-11-16 |
CA3169643A1 (en) | 2021-09-02 |
CN115551847A (zh) | 2022-12-30 |
AU2024201568A1 (en) | 2024-03-28 |
CA3169667A1 (en) | 2021-09-02 |
KR20220157407A (ko) | 2022-11-29 |
AU2021228286A1 (en) | 2022-10-06 |
MX2022010634A (es) | 2023-01-19 |
WO2021174170A9 (en) | 2022-09-15 |
EP4110774A1 (en) | 2023-01-04 |
KR20220158236A (ko) | 2022-11-30 |
EP4110771A1 (en) | 2023-01-04 |
MX2022010637A (es) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017089A2 (pt) | Derivados de piridazina para modular o splicing de ácido nucleico | |
BR112022017210A2 (pt) | Compostos e métodos para modulação de splicing | |
BR112022020337A2 (pt) | Compostos e métodos para modulação de splicing | |
BR112022020423A2 (pt) | Compostos e métodos para modulação de splicing | |
BR112023022592A2 (pt) | Cartucho de grampos compreendendo acionadores de grampos e suportes de estabilidade | |
BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
CL2022000603A1 (es) | Inhibidores prmt5 cooperativos de mta | |
CU20210080A7 (es) | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa | |
CR20140232A (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
PA8834001A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
BR112018075433A2 (pt) | derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os | |
CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
BR112014030386A8 (pt) | Compostos e composições para modular a atividade de egfr | |
CL2021001461A1 (es) | Moduladores de trex1 | |
BR112022005472A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica | |
MX2022010681A (es) | Compuestos y metodos para modular el empalme. | |
BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
BR112015024109A2 (pt) | derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp) | |
ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
BR112014015158B8 (pt) | uso de uma formulação, formulação, e, método para desenvolver plantas | |
BR112015012724A2 (pt) | derivados de álcoois 1-fenil-2-piridinil alquílicos como inibidores da fosfodiesterase | |
UY39368A (es) | Composiciones para modular el empalme | |
BR112022002815A2 (pt) | Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas |